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Abstract
Background: We examined the association between single nucleotide polymorphisms (SNPs) in
loci encoding surfactant protein A (SFTPA) and risk of wheeze and persistent cough during the first
year of life among a cohort of infants at risk for developing asthma.
Methods: Between September 1996 and December 1998, mothers of newborn infants were
invited to participate if they had an older child with clinician-diagnosed asthma. Each mother was
given a standardized questionnaire within 4 months of her infant's birth. Infant respiratory
symptoms were collected during quarterly telephone interviews at 6, 9 and 12 months of age. Due
to the association of SFTPA polymorphisms and race/ethnicity, analyses were restricted to 221
white infants for whom whole blood and respiratory data were available. Ordered logistic
regression models were used to examine the association between respiratory symptom frequency
and SFTPA haplotypes.
Results: The 6A allele haplotype of SFTPA1, with an estimated frequency of 6% among our study
infants, was associated with an increased risk of persistent cough (OR 3.69, 95% CI 1.71, 7.98) and
wheeze (OR 4.72, 95% CI 2.20, 10.11). The 6A/1A haplotype of SFTPA, found among approximately
5% of the infants, was associated with an increased risk of persistent cough (OR 3.20, 95% CI 1.39,
7.36) and wheeze (OR 3.25, 95% CI 1.43, 7.37).
Conclusion: Polymorphisms within SFTPA loci may be associated with wheeze and persistent
cough in white infants at risk for asthma. These associations require replication and exploration in
other ethnic/racial groups.
Background
Wheeze and persistent cough in infants are serious respi-
ratory symptoms that can be triggered by respiratory infec-
tions and/or a variety of environmental exposures [1-3].
Surfactant protein A (SFTPA) is an abundant, multifunc-
tional protein that is secreted by airway epithelial cells
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and functions as part of the innate immune response.
SFTPA may be critical in protecting the lungs from infec-
tious agents and environmental exposures early in life
before the acquisition of specific immunity. SFTPA neu-
tralizes respiratory viruses such as influenza and respira-
tory syncytial virus (RSV) [4,5]. SFTPA also enhances the
uptake of bacteria and viruses by phagocytes [6-8]. In
addition to its role in protecting the lungs from microor-
ganisms, SFTPA has other important immunomodulatory
functions including binding aeroallergens [9].
SFTPA's role in protection of the lungs has led to explora-
tion of potential links between SFTPA and diseases of the
respiratory tract in infants and young children. Polymor-
phisms within SFTPA1  and  SFTPA2, two functional,
highly homologous SFTPA  genes [10-12] have been
linked to respiratory distress syndrome in infants [13-15],
severe RSV bronchiolitis [16], and otitis media [17,18]. In
the present study, we used a candidate gene approach to
investigate whether polymorphisms within the SFTPA1
and SFTPA2 genes were associated with wheeze and per-
sistent cough during the first year of life among a prospec-
tive birth cohort at risk for developing asthma.
Methods
Cohort
Between September 1996 and December 1998, we invited
women delivering babies in six hospitals in Connecticut
and Massachusetts to participate in a longitudinal study of
asthma development if they had at least one other child at
home under 12 years of age with physician-diagnosed
asthma. Infants enrolled in the cohort were considered at
risk for asthma due to their asthmatic siblings. We provide
a full description of the methods elsewhere [2,19].
Of the 1,002 infants originally enrolled, respiratory symp-
tom data were available for the first year of life for 889.
Between the third and fifth year of participation, we made
a second visit to the home to collect a blood sample from
our cohort subjects. The current analyses are based on a
convenience sample of 355 for whom whole blood and
complete respiratory symptom data were available. Nucle-
otide changes at amino acid (aa) 19, aa 62, and aa 133 in
SFTPA1, and aa 223 in SFTPA2 were significantly associ-
ated with ethnicity. To prevent identification of invalid
associations due to population stratification, we restricted
our haplotype analyses to the ethnic group with the larg-
est number of subjects (221 white infants). The Yale
Human Investigations Committee and institutional
review boards at each participating hospital reviewed and
approved the study.
Data collection
A research assistant visited the home within 4 months of
the infant's birth in order to describe the study to the
infant's mother, obtain written informed consent, and
administer a standardized questionnaire. We collected
household demographic data including maternal race and
ethnicity, education and number of children; detailed
information regarding infant care (e.g. breastfeeding and
daycare use); and maternal health status (e.g. self-reported
history of allergies or physician-diagnosed asthma).
Infant respiratory symptoms were collected during quar-
terly telephone interviews at 6, 9 and 12 months of age at
which time each mother reported on her infant's respira-
tory symptoms (number of symptom-days per month of
wheeze or persistent cough) and doctor or clinic visits
(month and year of visit, reason for visit, and diagnosis).
Around the time of the infant's first birthday, the mother
completed an additional phone questionnaire covering
her infant's health status during the previous year.
Genotyping of SFTPA genes
DNA was extracted from whole blood using the QIAamp
DNA blood minikit (Qiagen) according to the manufac-
turer's instructions. We used sequence specific primer-
PCR methodology to genotype the SNPs at aa 19, aa 50,
aa 62, aa 133, and aa 219 in SFTPA1 and aa 9, aa 91, aa
223 in SFTPA2  [20]. We used PCR based cRFLP as
described by DiAngelo et al. [21] to detect polymor-
phisms in SFTPA2 at aa 140.
Data analysis
Outcomes of interest were respiratory symptom frequency
in the first year of life categorized as none or as 1 to 7, 8
to 14, 15 to 21, 22 to 28, or more than 28 days of persist-
ent cough or wheeze. Between 1 and 6 months of symp-
tom information were missing for 18 infants. Data from
these infants were included in analyses based on their
symptom rates. All other infants had 12 months of com-
plete symptom data. Unadjusted associations between
respiratory symptoms and selected study characteristics,
SNPs, and individual SFTPA1 or SFTPA2 alleles were eval-
uated with tests for linear trend (Cochran-Armitage or
Somers' D statistic). For statistical tests involving SNPs,
frequencies for the minor homozygous allele and hetero-
zygous alleles were combined and compared to the dom-
inant homozygous group. Observed SNP frequencies were
tested for Hardy-Weinberg equilibrium by χ2 analyses. We
examined pairwise linkage disequilibrium with r2 meas-
ures (Fig. 1) using PROC ALLELE of the SAS/Genetics
module of SAS version 9.1 [22]. Allele haplotypes for
SFTPA1 and for SFTPA2 were assigned and examined for
linkage disequilibrium using PROC HAPLOTYPE [22].
We examined the association between haplotype and res-
piratory symptom frequency (as categorical variables)
using ordered logistic regression. Separate analyses wereBMC Medical Genetics 2007, 8:15 http://www.biomedcentral.com/1471-2350/8/15
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conducted for each symptom and each haplotype com-
pared to all other haplotypes. We estimated the effect of
uncertainty in haplotype assignment using a regression
calibration technique [18,23] and the SFTPA1  and
SFTPA2  haplotype probabilities obtained from PROC
HAPLOTYPE. As described previously [18], this technique
involved first creating 100 separate haplotype data sets by
randomly assigning subject haplotypes based on each
subject's haplotype probabilities. Next, 100 separate
ordered logistic regression models with coefficient and
variance estimates (βi and σi 
2 for the ith model) were fit for
each haplotype of interest. The estimate of the association
between the respiratory symptom and the particular hap-
lotype of interest (  ) was calculated as the mean of the
100 regression models. The variability of the estimate was
calculated as
var ( ) = mean ( ) + var (bis)
where mean ( ) is defined as the mean of the 100 logis-
tic regression variances and var (bis) is defined as the var-
iance of the 100 logistic regression b coefficients.
Results
Close to half of the 221 infants in our study experienced
persistent cough (51%) or wheeze (46%) during their first
year of life (Table 1). Thirty-two percent of the infants
experienced from 1 to 28 days of persistent cough, 19%
experienced more than 28 days of persistent cough during
their first year; 36% experienced 1 to 28 days of wheeze
and 10% experienced more than 28 days of wheeze dur-
ing their first year of life. Male infants and infants of asth-
matic mothers were more likely to experience persistent
cough and wheeze during their first year of life (Table 1).
We did not find significant associations with either per-
sistent cough or wheeze and maternal allergies, age day-
care attendance began, number of months of
breastfeeding, or exposure to environmental tobacco
smoke (ETS).
Table 2 contains unadjusted associations between each of
the nine candidate SNPs and persistent cough or wheeze.
Individual SNPs were in Hardy-Weinberg equilibrium (p
> 0.05 for the χ2 test). Having a C nucleotide at aa 19 in
SFTPA1 was associated with greater frequency of wheeze.
The G nucleotide at aa 133 was associated with both
wheeze and persistent cough during the first year of life.
We did not find any significant associations between each
of the nine SNPs and personal characteristics listed in
Table 1.
ˆ β
ˆ β σi
2
σi
2
Pairwise linkage disequilibrium measure (r2) for surfactant protein A SNPs (5 SFTPA1 SNPs: aa 19, aa 50, aa 62, aa 133, aa 219;  4 SFTPA2 SNPs: aa 9, aa 91 aa 140, aa 223) from 221 white infants at risk for developing asthma Figure 1
Pairwise linkage disequilibrium measure (r2) for surfactant protein A SNPs (5 SFTPA1 SNPs: aa 19, aa 50, aa 62, aa 133, aa 219; 
4 SFTPA2 SNPs: aa 9, aa 91 aa 140, aa 223) from 221 white infants at risk for developing asthma. Gray scale represents strength 
of association from white (r2 = 0) to black (r2 = 1). (CT and MA, 1998 – 2000)B
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Table 1: Unadjusted associations between personal characteristics and respiratory symptoms during the first year of life for 221 white infants at risk for developing asthma. (CT and 
MA, 1998 – 2000)
Persistent cough (days/year) (%) Wheeze (days/year) (%)
Characteristic n (%) 0 1 – 7 8 – 14 15 – 21 22 – 28 > 28 p-valuea 0 1 – 7 8 – 14 15 – 21 22 – 28 > 28 p-valuea
White infants N (%) 221 109 (49.3) 30 (13.6) 19 (8.6) 12 (5.4) 10 (4.5) 41 (18.6) 119 (54.3) 49 (22.4) 17 (7.8) 7 (3.2) 6 (2.7) 21 (9.6)
Gender
male 115 (52.0) 42.6 14.8 11.3 7.0 7.0 17.4 0.12 44.2 27.4 8.0 3.5 4.4 12.4 0.005
female 106 (48.0) 56.6 14.3 5.7 3.8 1.9 19.8 58.0 17.0 7.6 2.8 0.9 6.6
Maternal allergies
No 81 (36.7) 44.4 17.3 8.6 3.7 2.5 23.5 0.20 52.5 21.2 10.0 3.8 2.5 10.0 0.35
Yes 140 (63.4) 52.1 11.4 8.6 6.4 5.7 15.7 55.4 23.0 6.5 2.9 2.9 9.4
Maternal asthma
No 153 (69.2) 52.3 15.0 9.2 5.2 2.0 16.3 0.02 57.2 23.7 7.9 2.6 0.7 7.9 0.01
Yes 68 (30.7) 42.6 10.3 7.4 5.9 10.3 23.5 47.8 19.4 7.5 4.5 7.5 13.4
Daycare (starting 
age in months)
1 – 5 43 (19.6) 48.8 14.0 9.3 2.3 7.0 18.6 0.26 55.8 14.0 11.6 2.3 4.6 11.6 0.45
6 – 12 21 (9.6) 57.1 9.5 19.0 4.8 0.0 9.5 55.0 30.0 10.0 0.0 0.0 0.5
None in first year 155 (70.8) 49.0 14.2 6.4 6.4 4.5 19.4 53.9 24.0 6.5 3.9 2.6 9.1
Breast feeding 
(duration in 
months)
None 49 (22.3) 53.1 14.3 6.1 4.1 0.0 22.4 0.25 49.0 18.4 10.2 2.0 6.1 14.3 0.15
1 – 5 57 (25.9) 49.1 19.3 3.5 7.0 5.3 15.8 57.9 19.3 3.5 3.5 1.8 14.0
6 – 12 114 (51.8) 47.4 10.5 12.3 5.3 6.1 18.4 54.5 25.9 8.9 3.6 1.8 5.4
ETS
No 197 (89.6) 48.7 12.2 9.6 5.6 4.6 19.3 0.19 55.4 20.5 8.7 3.1 3.1 9.2 0.38
Yes 23 (10.4) 52.2 26.1 0.0 4.4 4.4 13.0 43.5 39.1 0.0 4.4 0.0 13.0
ap-values from test for trend: Cochran-Armitage exact test (1-sided) for gender, maternal allergies, maternal asthma, Environmental Tobacco Smoke (ETS); Somer's D statistic (1-sided) for age when 
starting daycare and duration of breastfeeding. Significant p-values (p < 0.05) in bold-face type.B
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Table 2: Unadjusted associations between SNPs from surfactant protein A alleles (SFTPA1,SFTPA2) and respiratory symptomsa during the first year of life for white infants at risk for 
developing asthma. (CT and MA, 1998 – 2000)
Persistent cough (days/year) (%) Wheeze (days/year) (%)
Characteristic n (%) 0 1 – 7 8 – 14 15 – 21 22 – 28 > 28 p-valueb 0 1 – 7 8 – 14 15 – 21 22 – 28 > 28 p-valueb
White infants N (%) 221 109 (49.3) 30 (13.6) 19 (8.6) 12 (5.4) 10 (4.5) 41 (18.6) 119 (54.3) 49 (22.4) 17 (7.8) 7 (3.2) 6 (2.7) 21 (9.6)
SFTPA1 c
aa 19 (rs1059047)
CC 1 (0.4)
CT 42 (19.0) 46.5 7.0 11.6 7.0 2.3 25.6 0.15 44.2 18.6 11.6 4.6 7.0 14.0 0.02
TT 178 (80.5) 49.7 14.9 8.0 5.1 5.1 17.1 56.6 23.1 6.9 2.9 1.7 8.7
aa 50 (rs1136450)
CC 48 (21.4)
CG 103 (46.0) 51.7 10.9 8.2 6.1 3.4 19.7 0.50 53.4 22.6 8.9 2.7 3.4 8.9 0.51
GG 73 (32.6) 45.2 17.8 9.6 4.1 6.8 16.4 55.6 22.2 5.6 4.2 1.4 11.1
aa 62 (rs1136451)
GG 5 (2.2)
AG 61 (27.5) 45.3 7.8 14.1 6.2 3.1 23.4 0.11 46.9 21.9 10.9 3.1 6.2 10.9 0.07
AA 156 (70.3) 51.3 15.6 6.5 4.6 5.2 16.9 57.9 21.7 6.6 3.3 1.3 9.2
aa 133 
(rs1059057)
GG 1 (0.4)
AG 38 (16.9) 36.8 7.9 13.2 7.9 2.6 31.6 0.02 39.5 18.4 10.5 5.3 10.5 15.8 0.003
AA 186 (82.7) 51.9 14.8 7.6 4.9 4.9 15.8 57.5 23.2 7.2 2.8 1.1 8.3
aa 219 
(rs4253527)
TT 1 (0.4)
CT 34 (15.1) 52.9 11.8 20.6 2.9 0.0 11.8 0.12 55.9 29.4 11.8 0.0 0.0 2.9 0.06B
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CC 190 (84.4) 48.7 13.9 6.4 5.9 5.4 19.8 54.0 21.1 7.0 3.9 3.2 10.8
SFTPA2 c
aa 9 
(rs1059046)
CC 42 (18.7)
AC 109 (48.4) 52.4 11.6 9.5 4.1 3.4 19.0 0.26 55.1 21.1 8.8 2.0 3.4 9.5 0.50
AA 74 (32.9) 43.2 17.6 6.8 8.1 6.7 17.6 52.8 25.0 5.6 5.6 1.4 9.7
aa 91 
(rs17886395)
CC 3 (1.4)
CG 57 (25.7) 50.8 8.5 10.2 5.1 3.4 22.0 0.33 54.2 18.6 6.8 3.4 8.5 8.5 0.23
GG 162 (73.0) 49.1 15.1 8.2 5.7 5.0 17.0 54.8 23.6 8.3 3.2 0.6 9.6
aa 140 
(rs1965707)
TT 13 (5.8)
CT 87 (38.8) 53.1 15.3 8.2 2.0 2.0 19.4 0.15 53.1 24.5 10.2 3.1 2.0 7.1 0.24
CC 124 (55.4) 45.9 12.3 9.0 8.2 6.6 18.0 55.0 20.8 5.8 3.3 3.3 11.7
aa 223 
(rs1965708)
AA 7 (3.1)
AC 71 (31.6) 54.0 11.8 9.2 2.7 4.0 18.4 0.27 55.3 23.7 9.2 4.0 1.3 6.6 0.18
CC 147 (65.3) 46.9 14.5 8.3 6.9 4.8 18.6 53.8 21.7 7.0 2.8 3.5 11.2
aN = 221 infants had data for persistent cough and N = 219 for wheeze during the first year of life. bp-values from test for trend: Cochran-Armitage exact test (1-sided). Minor homozygotes and 
heterozygous alleles were combined and compared to the dominant homozygous group. Significant p-values (p < 0.05) in bold-face type. c SNPs were in Hardy-Weinberg equilibrium. rs numbers are 
given in parentheses next to each amino acid.
Table 2: Unadjusted associations between SNPs from surfactant protein A alleles (SFTPA1,SFTPA2) and respiratory symptomsa during the first year of life for white infants at risk for 
developing asthma. (CT and MA, 1998 – 2000) (Continued)BMC Medical Genetics 2007, 8:15 http://www.biomedcentral.com/1471-2350/8/15
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By convention, SFTPA1 and SFTPA2 allele haplotypes are
denoted by 6An and 1Am respectively [17,21]. The esti-
mated frequency of each allele haplotype is given in Table
3. The five SNPs in SFTPA1 were in linkage disequilibrium
as were the four SNPs in SFTPA2 (p < 0.0001, χ2 test of
allelic associations).
The most common SFTPA1  allele haplotypes among
white infants in our study population were 6A2, 6A3, 6A4,
and 6A in order of decreasing frequency. All others made
up 8% of the SFTPA1 alleles. 1A0 was the most common
SFTPA2 allele followed in order by 1A1, 1A2, 1A, 1A5, 1A6,
and 1A3. All others combined made up 4% of the SFTPA2
alleles.
Significant associations were found between specific allele
haplotypes and frequency of persistent cough or wheeze
during the first year of life (Table 3). The 6A haplotype of
SFTPA1 was a risk factor for both persistent cough and
wheeze: infants with this haplotype (an estimated 6% of
this group of white infants) were 3.7 to 4.7 times more
likely to experience an additional week of persistent
cough or wheeze, respectively, during their first year than
infants without this haplotype.
SFTPA1 and SFTPA2 alleles are known to be in strong
linkage disequilibrium [24,25]. This was also true in our
population of white infants in a general test of allelic asso-
ciations (p < 0.0001, χ2 test), although pairwise linkage
Table 3: Unadjusted associations between surfactant protein A (SFTPA1,SFTPA2) haplotypes and persistent cough or wheeze in the first 
year of life.a Unadjusted odds ratios (OR) and 95% confidence intervals (CI) are from ordered logistic regression models predicting 
symptom frequency. b (CT and MA, 1998 – 2000)
Allele, haplotypec Nucleotide/amino acidd Estimated Frequency
Distributione% (95% CI)
Persistent Cough
OR (95% CI)
Wheeze
OR (95% CI)
SFTPA1 aa 19 aa 50 aa 62 aa 133 aa 219
6A C/Ala C/Leu G G C/Arg 6.1% (4.0 – 8.3) 3.69 (1.71, 7.98) 4.72 (2.20, 10.11)
6A2 T/Val G/Val A A C/Arg 54.0% (49.3 – 58.7) 1.18 (0.63, 2.19) 1.13 (0.60, 2.14)
6A3 T/Val C/Leu A A C/Arg 25.6% (21.6 – 29.6) 0.81 (0.49, 1.36) 0.83 (0.49, 1.40)
6A4 T/Val C/Leu G A T/Trp 6.2% (4.1 – 8.4) 0.94 (0.44, 2.03) 0.70 (0.31, 1.60)
all others 8%
SFTPA2 aa 9 aa 91 aa 140 aa 223
1A C/Thr C/Pro C C/Gln 8.4% (6.0 – 10.8) 1.53 (0.75, 3.14) 1.30 (0.63, 2.71)
1A0 A/Asn G/Ala C C/Gln 54.2% (49.5 – 58.8) 1.13 (0.60, 2.13) 1.14 (0.59, 2.19)
1A1 C/Thr G/Ala T A/Lys 13.7% (10.7 – 16.7) 0.82 (0.45, 1.48) 0.87 (0.47, 1.58)
1A2 C/Thr G/Ala C C/Gln 10.2% (7.6 – 12.7) 0.95 (0.49, 1.84) 0.83 (0.42, 1.64)
1A3 A/Asn G/Ala T A/Lys 1.8% (0.7 – 2.9) 0.45 (0.08, 2.48) 0.55 (0.10, 3.06)
1A5 C/Thr C/Pro T C/Gln 4.6% (2.7 – 6.5) 0.43 (0.15, 1.23) 0.66 (0.24, 1.79)
1A6 C/Thr G/Ala T C/Gln 3.2% (1.7 – 4.7) 1.41 (0.49, 4.05) 1.54 (0.54, 4.39)
all others 4%
SFTPA Haplotype
6A/1A 5.4% (3.2 – 7.2) 3.20 (1.39, 7.36) 3.25 (1.43, 7.37)
6A2/1A0 49.0% (44.4 – 53.6) 1.20 (0.66, 2.19) 1.04 (0.57, 1.90)
6A2/1A2 1.8% (0.6 – 2.9) 1.43 (0.36, 5.70) 0.26 (0.03, 1.99)
6A2/1A3 1.0% (0.2 – 1.9) 0.65 (0.10, 4.39) 0.79 (0.11, 5.47)
6A3/1A0 4.7% (2.8 – 6.6) 1.16 (0.49, 2.74) 0.92 (0.37, 2.31)
6A3/1A1 11.3% (8.5 – 14.1) 1.12 (0.60, 2.08) 1.08 (0.57, 2.04)
6A3/1A2 5.6% (3.6 – 7.6) 0.93 (0.40, 2.16) 0.92 (0.39, 2.17)
6A3/1A6 1.7% (0.5 – 2.8) 0.91 (0.21, 4.07) 2.26 (0.55, 9.33)
6A4/1A5 2.9% (1.4 – 4.4) 0.28 (0.07, 1.07) 0.30 (0.08, 1.20)
6A4/1A6 1.8% (0.6 – 3.0) 1.88 (0.49, 7.16) 1.69 (0.44, 6.39)
Others 14.9%
aAnalyses included infants with complete data for both SFTPA alleles and respiratory symptoms, i.e., for SFTPA1 and persistent cough (N = 203) or 
wheeze (N = 202); SFTPA2 and persistent cough (N = 205) or wheeze (N = 204); SFTPA and persistent cough (N = 201) or wheeze (N = 200). 
bSeparate ordered logistic regression analyses were performed for each outcome measure and each haplotype with all other haplotypes serving as 
the reference group in each model. All model results (ORs [95% CI]) include estimates of model variabillity due to ambiguity in allele haplotype 
assignment (see text). Number of days per year of symptoms were included in models as a 6-category variable, i.e., 0, 1–7, 8–14, 15–21, 22–28, > 28 
days. Significant results (p < 0.05) are in bold-face type. c By convention, SFTPA1 allele haplotypes are denoted by 6An and SFTPA2 allele haplotypes 
by 1Am [17,21]. daa 62, aa 133 and aa 140 are silent. eEstimated frequency distribution of haplotypes (mean, 95% CI) for white infants.BMC Medical Genetics 2007, 8:15 http://www.biomedcentral.com/1471-2350/8/15
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disequilibrium measures (r2) for SNPs within SFTPA
reveal a spectrum of associations from r2 = 0 to 0.6 (Fig.
1). An examination of SFTPA1  and  SFTPA2  alleles
together indicates that infants with the 6A/1A haplotype,
an estimated 5.4% of this group, were over 3 times more
likely to experience an additional week of persistent
cough and/or wheeze during their first year than infants
without this haplotype (Table 3).
Discussion and conclusion
Results from our study suggest that the 6A allele haplotype
of SFTPA1 and the 6A/1A haplotype of SFTPA are associ-
ated with increased risk for wheeze and persistent cough
among infants at risk for asthma. To our knowledge, this
is the first study examining the association of polymor-
phisms in SFTPA with persistent cough and wheeze in
infants. Respiratory symptoms may be triggered by bacte-
rial or viral respiratory infections or exposure to environ-
mental contaminants. This is certainly true for children in
our birth cohort [2,3,19]. As reported previously [2],
among all children in our birth cohort, infants whose
mothers reported respiratory illnesses including bronchi-
tis, bronchiolitis, pneumonia, or croup, were 3 to 5 times
more likely to experience persistent cough or wheeze in
the first year of life than infants who had no respiratory ill-
ness in their first year. Among these same infants, respira-
tory symptoms have also been linked to household
exposures such as NO2 [3] and mold [2,19].
SFTPA likely plays multiple pleiotropic roles in the patho-
physiology of the lung. Evidence from animal and human
studies suggests an important role for SFTPA in protecting
infants and young children during microbial infections
early in life. SFTPA deficient mice are impaired in their
ability to clear adenovirus from the lung [24]. SFTPA
knockout mice show delayed clearance of Haemophilus
influenzae  [25]. Cell culture assays indicate that SFTPA
enhances phagocytosis of H. influenzae and Streptococcus
pneumoniae [26].
Among infants, polymorphisms in SFTPA have been asso-
ciated with severe bronchiolitis [16]. The 6A2/1A3 haplo-
type was associated with increased risk of severe RSV
infection (OR 10.4 95% CI 1.3–83.2) and haplotype 6A/
1A was protective for severe disease (OR 0.17 95% CI
0.04–0.80). In this study of Finnish infants, cases were
hospitalized infants with documented bronchilotis
caused by RSV. Controls, matched on sex and age, had no
history of respiratory infections requiring hospitalization,
but might have had respiratory infections (and symp-
toms) not requiring hospitalization. Although we identi-
fied 6A/1A with increased risk for wheeze and persistent
cough, it is interesting that the 6A/1A haplotype is associ-
ated with respiratory problems in both populations.
Direct comparison between the two studies is difficult
because of differences in study design. In our study,
"cases" were defined by reported respiratory symptoms.
Specific causal agents were not identified, and we did not
use hospitalization as a requirement for inclusion. Thus,
some of our study subjects could resemble Finnish cases
(hospitalized for RSV) or controls (not hospitalized, but
possibly suffering from respiratory infection and exhibit-
ing respiratory symptoms).
SFTPA has been shown to bind to aeroallergens including
inhalable extracts from the mold Aspergillus fumigatus [27]
and from the mite Dermatophagoides pteronyssinus (Der p)
[28]. SFTPA has also been postulated to play a role in
allergic asthma [29]. A murine model of asthma indicates
that SFTPA mRNA and protein levels increase in response
to allergen challenge [30]. SFTPA decreases Der p induced
lymphocyte proliferation and histamine release from the
blood of atopic donors [31]. SFTPA has also been impli-
cated in bronchial inflammation of sensitized mice [32].
All infants in our cohort have at least one sibling with
asthma and one-third have asthmatic mothers (Table 1).
Two-thirds of the infants have mothers with allergies
(Table 1). The children in our cohort experienced high
rates of wheeze (46%) during their first year of life (Table
1). Among a cohort of 890 healthy infants in Connecticut
and Virginia born between 1993–1996, 33% experienced
an episode of wheeze during the winter months of their
first year of life [34]. The high rate of wheeze in our study
population may reflect the special nature of our cohort: all
are considered to be at risk for developing asthma. Along
these same lines, SFTPA may play a role in the pathogen-
esis of asthma, and infants in our cohort, by virtue of their
family histories of asthma, may differ in SFTPA1  and
SFTPA2 hapylotype distributions compared to the general
population. Population based estimates of SFTPA1 allele
haplotype frequencies among white Americans are 56.2%
6A2, 24.3% 6A3, 9.3% 6A, 7.6% 6A4 and 2.6% other [33].
Allele haplotype frequencies for SFTPA2  are 53% 1A0,
10.2% 1A, 14.3% 1A1, 7.6% 1A2, and 14.9% all others
[33]. With the notable exception of the SFTPA1 allele hap-
lotype 6A, the distribution of SFTPA1 and SFTPA2 haplo-
types in our sample of white infants is similar to that of
white Americans in the general population. The general
population frequency for 6A of 9.3% is higher than the
95% confidence interval for our estimate of 6.1% (95% CI
4.0–8.3), which may indicate a true difference in fre-
quency for this allele haplotype among our group of
infants.
The functional significance of specific changes in nucleo-
tide sequence within SFTPA genes has not been well stud-
ied.  SFTPA  is a member of the collectin family and
recognizes carbohydrates on the surface of pathogens via
their carbohydrate recognition domain [35]. Allele 6A isBMC Medical Genetics 2007, 8:15 http://www.biomedcentral.com/1471-2350/8/15
Page 9 of 10
(page number not for citation purposes)
the only common haplotype in our population with an
alanine at aa 19 and a G at aa 133. The SNP at aa 133 is
silent, however, aa 19 is in the N terminal region of
SFTPA1 and an alanine in this region could conceivably
impact binding to pathogens or aeroallergens. Further
experiments are needed to identify whether amino acid
changes in this region impact the biological properties of
SFTPA. Alternatively, the 6A haplotype may simply be a
marker for additional uncharacterized functional poly-
morphisms in our cohort.
Strengths of this study include the prospective study
design and the well characterized demographic, illness,
and environmental exposure information for the infant
cohort. Mothers in this study were likely capable of accu-
rately reporting respiratory symptoms due to their famili-
arity with wheeze and persistent cough in the older
asthmatic child. Haplotype analyses often use the "most
likely" haplotype and seldom include adjustments for
uncertainty in haplotype assignment. We used regression
calibration techniques that incorporate this uncertainty
into estimates of the effect resulting in more conservative
estimates of the true associations between SFTPA and per-
sistent cough or wheeze during the first year of life.
Our results support the importance of SFTPA in modulat-
ing respiratory symptoms in infants. Persistent cough and
wheeze may result from a variety of exposures and the
multifunctional nature of SFTPA indicates that it protects
the lung under a variety of conditions. The 6A/1A haplo-
type may have a functional role in pathogenic processes,
or may be linked to unmeasured markers that are causal.
Future studies should replicate these observations and
examine polymorphisms within SFTPA among additional
racial and ethnic groups.
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